Trending Now
Stability and Dividend Potential of Healthcare Stocks (GILD,BMY,DHR)
Recent market volatility has shifted investor focus on on stability and dividend potential of healthcare stocks. The focus is on pharmaceutical and...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Pharmadrug Inc. (CNSX:BUZZ) Sets Sights ON Germany Psychedelics Opportunity
Pharmadrug Inc. (CNSX:BUZZ) is positioning itself for the tremendous opportunity up for grabs around psychedelic distribution in Europe. Germany’s Federal Institute of Drugs and...
MAKE IT MODERN
LATEST REVIEWS
S&P 500 could move higher as per technical analysis (ARM, S&P)
We broke through the 50 SMA yesterday with a strong move higher as SPY closed up nearly $4 per share. Next chart...
MAKE IT MODERN
PERFORMANCE TRAINING
Briacell Therapeutics Corp (NASDAQ: BCTX) Receives the Fast Track Designation For Bria-IMT
Briacell Therapeutics Corp (NASDAQ: BCTX) has received U.S FDA Fast Track Designation for Bria-IMT. This therapy is for metastatic breast cancer. The company is...
The US Flirts with SPR Release but Energy Trend Points Higher (HP, HNRC, PDCE,...
The U.S. is eying the controversial step of tapping the Strategic Petroleum Reserve, a foundational deposit of oil housed in the US...
Top Analysts Say Metaverse is a Trillion Dollar Opportunity (SNAP, SFLM, FSLY, U, MTTR,...
Just how much will the Metaverse be worth for investors over coming years? According to JPMorgan’s most recent analysis, the market opportunity...
Aeterna Zentaris Starts Preclinical Program For The Potential Treatment Of Primary Hypoparathyroidism
Aeterna Zentaris launched a preclinical development program to develop parathyroid hormone fusion polypeptides (PTH) to treat primary hypoparathyroidism. The company will pursue the program...
Neurosense Therapeutics Ltd (NASDAQ: NRSN) Earns $4 Million After Exercising Warrants
Neurosense Therapeutics Ltd (NASDAQ: NRSN) received $4 million in proceeds after exercising warrants valued at $6 let share. The company issued these...
MAKE IT MODERN
